drugset / Trial / NCT00667628

Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma

NCT00667628 ↗

Phase 2 Terminated 54 enrolled Taiho Oncology, Inc. Quintiles, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether TAC-101 combined with Transcatheter Arterial Chemoembolization (TACE) is more effective than TACE alone in slowing tumor activity in patients with advanced hepatocellular carcinoma. The study is also looking at the safety of TAC-101 in combination with TACE.

Timeline

Start
2008-04-24
Primary completion
2009-12-22
Completion
2009-12-22

Outcome

Outcome not reported

Stopped: “Terminated due to safety concerns.”

Drugs

EvaluationDrugModalityDoseRoute
Subject AMSILAROTENE Small molecule 20 mg Oral